Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

616 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis.
Sciumè M, Serpenti F, Zanotti R, Bonadonna P, Tanasi I, Crosera L, Elena C, Mannelli F, Crupi F, Papayannidis C, Sartor C, Soverini S, Rondoni M, Eller-Vainicher C, Pravettoni V, Rivolta F, Alberti Violetti S, Croci GA, Migliorini AC, Bolli N, Giannarelli D, Grifoni FI. Sciumè M, et al. Among authors: giannarelli d. Hematol Oncol. 2024 May;42(3):e3277. doi: 10.1002/hon.3277. Hematol Oncol. 2024. PMID: 38682493 No abstract available.
Implications of Genetic, Biological and Clinical Parameters in Patients With Richter Syndrome: A Monocentric Experience.
Innocenti I, Quaranta T, Tomasso A, Mosca A, Benintende G, Fresa A, Larocca LM, Stirparo L, Iadevaia F, Vuono F, Bellesi S, Bakacs A, Efremov D, Gattei V, Giannarelli D, Autore F, Laurenti L. Innocenti I, et al. Among authors: giannarelli d. Hematol Oncol. 2025 Jan;43(1):e70028. doi: 10.1002/hon.70028. Hematol Oncol. 2025. PMID: 39729577 No abstract available.
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study.
Ascierto PA, Cioli E, Chiarion-Sileni V, Quaglino P, Spagnolo F, Guidoboni M, Del Vecchio M, Peris K, Queirolo P, Fioretto L, Caracò C, Paone M, Sorrentino A, Capone M, Giannarelli D, Ferrara G, Massi D, Trojaniello C. Ascierto PA, et al. Among authors: giannarelli d. Front Oncol. 2023 Feb 9;13:1107307. doi: 10.3389/fonc.2023.1107307. eCollection 2023. Front Oncol. 2023. PMID: 36845751 Free PMC article.
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?
Corianò M, Giannarelli D, Scartabellati G, De Giorgi U, Brighi N, Fornarini G, Tommasi C, Giudice GC, Rebuzzi SE, Puglisi S, Caffo O, Kinspergher S, Mennitto A, Cattrini C, Santoni M, Verzoni E, Rametta A, Stellato M, Malgeri A, Roviello G, Brunelli M, Signori A, Banna GL, Buti S. Corianò M, et al. Among authors: giannarelli d. Expert Rev Anticancer Ther. 2023 May;23(5):545-554. doi: 10.1080/14737140.2023.2200168. Epub 2023 Apr 10. Expert Rev Anticancer Ther. 2023. PMID: 37017710
Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study.
Nelli F, Fabbri A, Botticelli A, Giannarelli D, Marrucci E, Fiore C, Virtuoso A, Berrios JRG, Scagnoli S, Pisegna S, Cirillo A, Panichi V, Massari A, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: giannarelli d. Front Oncol. 2023 Nov 7;13:1280416. doi: 10.3389/fonc.2023.1280416. eCollection 2023. Front Oncol. 2023. PMID: 38023235 Free PMC article.
Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status.
Marchetti C, Ataseven B, Perrone AM, Cassani C, Fruscio R, Sassu CM, Apostol AI, Harter P, De Iaco P, Camnasio CA, Moubarak M, Giannarelli D, Scambia G, Fagotti A. Marchetti C, et al. Among authors: giannarelli d. Gynecol Oncol. 2024 Aug;187:170-177. doi: 10.1016/j.ygyno.2024.05.008. Epub 2024 May 23. Gynecol Oncol. 2024. PMID: 38788514
Distribution and prognostic role of BRCA status in elderly ovarian cancer patients.
Tortorella L, Cappuccio S, Giannarelli D, Nero C, Marchetti C, Gallotta V, Costantini B, Pasciuto T, Minucci A, Fagotti A, Scambia G. Tortorella L, et al. Among authors: giannarelli d. Gynecol Oncol. 2024 Mar;182:57-62. doi: 10.1016/j.ygyno.2023.12.022. Epub 2024 Jan 22. Gynecol Oncol. 2024. PMID: 38262239 Free article.
Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
Musacchio L, Palluzzi E, Di Napoli M, Lauria R, Ferrandina G, Angioli R, Bergamini A, Corrado G, Perniola G, Cassani C, Savarese A, Gori S, Greco F, De Angelis C, Zafarana E, Giannarelli D, Cinieri S, Mosconi AM, Raspagliesi F, Pignata S, Scambia G, Lorusso D. Musacchio L, et al. Among authors: giannarelli d. Gynecol Oncol. 2024 May;184:24-30. doi: 10.1016/j.ygyno.2024.01.022. Epub 2024 Jan 25. Gynecol Oncol. 2024. PMID: 38277918
616 results